Objective: DNA hypermethylation is an abnormal epigenetic process catalyzed by DNA methyltransferase 1 (DNMT1). It is also one of the factors that cause non-communicable diseases such as cancer, diabetes, and other metabolic diseases. DNA hypermethylation can be reversed by suppressing DNMT1 activity using a DNMT inhibitor. This study was conducted to seek out inhibitor candidates among natural products.
INTRODUCTION
Epigenetic modification is one of the factors that cause noncommunicable diseases. Living environment, lifestyle, exposure to toxic chemicals, and nutrition may influence an individual's epigenetic profile. Epigenetic modification can alter gene expression [1] . One type of epigenetic modification is DNA methylation. DNA methylation, catalyzed by DNA methyltransferases (DNMTs), is the addition of a methyl (CH3) group to the DNA strand, specifically to the fifth carbon atom of a cytosine ring. Methylated cytosine, called 5-methylcytosine, usually occurs to a cytosine base that lies adjacent to a guanine base, at what is called a CpG site. The reason for this name is that cytosine is bonded to guanine through a phosphate bond. These sites normally occur in clusters; an area rich in CpG sites is called a CpG island. CpG islands are usually located near a gene regulator such as a promoter. DNA methylation that affects a gene promoter may repress the transcription of said gene and ultimately its expression. This process of turning a gene on and off through methylation is part of normal eukaryotic cell function [2, 3] .
There are several types of DNMTs. Based on their functions, they can be grouped into two categories: De novo DNMTs, which form new methylated cytosine, and maintenance DNMTs, which maintain existing epigenetic patterns from one generation of cells to its offspring. In mammalian cells, there are three active DNMTs: DNMT1, DNMT3L, and DNMT3A/3B. DNMT1 is a maintenance DNMT, whereas DNMT3A/3B and DNMT3L are de novo DNMTs [4] . DNMT uses S-adenosyl-L-methionine as a methyl donor and produces S-adenosyl-Lhomocysteine (SAH) [5] . SAH is a strong endogenous inhibitor of DNMT. Hypermethylation is an aberrant methylation that occurs to normally unmethylated areas of the genetic sequence. Hypermethylation of CpG islands in the promoter region of a gene may cause inappropriate gene silencing and may affect such genes as those responsible for tumor suppression. It is, therefore, associated with non-communicable diseases such as cancer and diabetes [6] . One approach to recovering the function of a silenced gene is inhibiting the enzyme that catalyzes the methylation process, that is, DNMT. DNMT inhibitors (DNMTi's) exist as nucleoside analogs and non-nucleoside analogs [7] .
The development of non-communicable disease therapies that target the underlying epigenetic factors is paramount. Most of the existing therapies do not, and the limited number that do usually have severe side effects. These side effects arise because the existing epigenetic therapies use nucleoside analogs, which have similar structures to nucleosides and therefore interfere with normal cell function. The recent studies have focused on the finding non-nucleoside analog inhibitor candidates from natural sources [8, 9] . Natural products are promising non-nucleoside DNMTi candidates because of their relatively low toxicity and high structural diversity [10, 11] . The potential of several natural products has been studied; these products have included curcumin [12] , epigallocatechin (EGCG) [13] , genistein [14] , caffeic acid [15] , psammaplin A [16] , mahanine [17] , and laccaic acid [16] . However, the inhibitory effects of these natural compounds are relatively low [11] . Therefore, a search for more effective DNMTi's from natural compounds is necessary. Indonesia is recognized for its biodiversity, with at least 9600 species known to possess pharmacological activity [18, 19] , so a search for a DNMTi is promising. A previous study conducted by Yanuar et al. [20] collected three-dimensional data on several Indonesian herbal compounds and compiled a database, published as the Indonesian Herbal Database (HerbalDB). In this study, virtual screening was employed as an in silico method of structure-based drug design. The virtual screening was done on the HerbalDB using AutoDock and AutoDockVina in the PyRx software [21] [22] [23] . The software was validated using decoys generated by the Directory of Useful Decoys, Enhanced (DUD-E) [24] .
METHODS
This study was conducted using literature and virtual screening by molecular docking (structure-based virtual screening). The materials and methods described in this study were modified from the studies by Yanuar et al., Syahdi et al., and Maldonado-Rojas et al. [11, 25, 26] . A three-dimensional structure of DNMT1, positive and negative control compounds, and active herbal compounds contained in the HerbalDB were used in this study.
Preparing the target protein structure
The structure of the docking target, DNMT1, was obtained from the Research Collaboratory for Structural Bioinformatics Protein Data Bank website at www.rcsb.org/pdb/home [27] . Several inclusion and exclusion criteria were used to select the DNMT structure. The selected structure was required to be present in humans (homo sapiens), include a complete amino acid sequence at the active site, and be in complex with a ligand. The structure could not be a mutant protein or have a resolution of more than 2.5 Å. UniProt, InterPro, and protein model portal were used to compare the sequences and lengths of the amino acid chains [28] [29] [30] . The selected structure was then downloaded and optimized. The optimization process included cleaning the structure of solutes and all chemical compounds other than the co-crystal ligand and the target protein, separating the protein from the co-crystal ligand, adding missing hydrogens and charges, and minimizing energy. The partial charge of the atoms was calculated using the Gasteiger-Marsili charge algorithm while the force field calculation and minimization were done using the MMFF 94 method [31, 32] . The entire optimization process was done using the Python molecular viewer embedded into AutoDock Tools. The coordinates of the center of the search space were then determined based on the binding space occupied by the co-crystal ligand.
Preparing the ligand structure
This study used three groups of ligands: Actives, decoys, and HerbalDB. The actives were positive controls or compounds that showed inhibitory activity against DNMT1 through in vitro or in vivo tests. Based on the previous research, 25 compounds were chosen as actives [11] [12] [13] [14] [15] [16] [17] . Their structures were obtained in SMILES format from the PubChem website at pubchem.ncbi.nlm.nih.gov [33] . These compounds are listed in Table 1 . The second ligand group consisted of negative controls, chemical structures generated by the DUD-E at http://dude.docking. org based on the chemical structures of the 25 active compounds. For the virtual screening parameter optimization process, the libraries of actives and decoys were combined. The third ligand library contained 1550 compounds, and all active metabolites found in the HerbalDB. The structures in all three groups were then converted to the mol2 file format using Open Babel [34] .
Validating the docking method
The validation of AutoDock 4.2 and AutoDockVina in PyRx was done by redocking the co-crystal ligand of the selected target protein. The varied parameters were grid center, grid spacing, and number of grid points, which in turn affected the binding energy, inhibition constant, and root-mean-square deviation (RMSD) of the docking results. The best pose was selected by evaluating the lowest binding energy and the lowest RMSD value. The protein-ligand interaction of the resulting pose was then compared to that of the co-crystals original pose and analyzed. Validation of both docking programs was also done on the actives library through docking to the target protein. The resulting binding energies were then used as references to determine the binding energy cutoff in the virtual screening process.
Optimizing the virtual screening parameters
The parameters for virtual screening were optimized by docking the active and decoy libraries to the target protein. The results were then calculated and analyzed through a receiver operating characteristic (ROC) curve and enrichment factors (EF) to determine the optimum parameters for each program, that is, the parameters that accurately discriminated actives from decoys without compromising too much accuracy or sensitivity.
Virtual screening of the HerbalDB
The virtual screening was performed on all active compounds in the HerbalDB using AutoDockVina in PyRx. The optimum parameters obtained from the previous step were applied to the docking software. The screening results were ranked by their binding affinity values, and the actives' lowest binding energy from the docking validation step was used as the cutoff value to determine the hit compounds. Compounds with binding affinities lower than this cutoff value were considered hits. 12 compounds met this criterion and were analyzed further.
Analyzing target-ligand interaction
The ligand poses, resulting from the virtual screening, were then visualized using PyMOL and LigPlot + and compared with the pose of the co-crystal ligand [35] . In the interaction between specific amino acids, the ligands, and the respective binding space, each ligand occupied was then analyzed and compared to that of the co-crystal ligand.
RESULTS AND DISCUSSION
The DNMT1 structure that met all the inclusion and exclusion criteria was therefore selected as the target protein was 3SWR. This structure is in complex with sinefungin (SFG). The ligand binding site was determined by the position of this co-crystal ligand. The coordinates were −5.235, −0.522, and −32.228 for the x-, y-, and z-axis, respectively. Analysis of the target-ligand interaction between SFG and 3SWR before the structure was optimized showed that the amino acids that interacted with DNMT1 were Phe1145, Leu1151, Glu1168, Met1169, Cys1191, Glu1266, and Val1580. SAH, which has one chemical group different from SFG, occupied the same hydrophobic pocket and showed the same amino acid interactions. Other research into inhibiting DNMT1 with SFG has shown similar interactions with these amino acids. The best redocking run of SFG to 3SWR with AutoDock yielded an RMSD value of 2.704 and a ∆G of −8.92 kcal/mol. The parameters used for this run were 60 × 60 × 60 grid points with a 0.375 Å space between points (Fig. 1) .
The docking of the actives library to the target protein showed that there were natural, non-nucleoside analog compounds with lower binding energies than SAH, which was also included in this library. Some of these compounds were laccaic acid A, EGCG, mahanine, genistein, parthenolide, curcumin, and chlorogenic acid. From this result, it can be surmised that a virtual screening process would detect non-nucleoside analog compounds with better binding affinities than the endogenous compound (SAH). The compounds that produced the lowest binding As can be observed in Fig. 2 , the validation parameter optimization in AutoDock failed to produce ROC values above 50%, indicating that the system discriminated actives from decoys randomly. Therefore, the virtual screening was not done in AutoDock. In AutoDockVina, the best ROC AUC and EF1% values were obtained from 60 × 60 × 60 grid points with 0.375 Å spacing (equivalent to 22.5 × 22.5 × 22.5 Å).
The results of the virtual screening of the HerbalDB using AutoDockVina are listed in Table 2 . The 12 compounds with binding energies lower than the cutoff value were cassiamin C (A1), procyanidin B2 (B2),
, cyanidin 3-(6''-caffeylsophorosid e)-5-glucoside (I9), epifriedelanol (J10), gallocatechin-(4alpha->8)-epicatechin (K11), and scutellarein 7-glucosyl-(1->4)-rhamnoside (L12). The lowest binding energy was that of A1 at −12.7 kcal/mol, whereas the highest was that of K11 at −11.5 kcal/mol. The optimization of the virtual screening parameters in PyRx showed that only AutoDockVina produced an acceptable validity. The grid box size used Analysis of all target-ligand interactions showed that out of the 12 compounds, B, C, D, E, and I interacted with 4 out of the 7 amino acids that SFG and SAH interacted with Phe1145, Met1169, Cys1191, and Glu1266. The other compounds interacted with adjacent amino acids and occupied a different binding space. Phe1145 and Met1169 interacted hydrophobically, either with SFG and SAH or with the VS compounds. In either SFG or SAH, Cys1191 interacted with N1 on the adenine ring, while in the VS compounds, Cys1191 interacted with the hydroxyl group on the B ring of catechin or epicatechin. Therefore, it can be concluded that these five compounds are possible DNMT1 inhibitors. Further, in vitro study is needed to confirm this premise. The results of all target-ligand analysis can be observed in Table 3 .
CONCLUSION
AutoDockVina in PyRx yields the best virtual screening result with the following parameters: A grid box center at −5.325, −0.522, and −32.228 and a grid box size at 22.5 × 22.5 × 22.5 Å (equivalent to grid point numbers of 60, 60, and 60 for the x-, y-, and z-axes, respectively, with 0.375 Å between points). A virtual screening conducted with these parameters produced 12 compounds with binding energy values lower than −11.1 kcal/mol. An analysis of protein-ligand interactions showed that five of these compounds interacted with many of the same amino acids as the reference compounds did. These five compounds were procyanidin B2, ent-epicatechin-(4alpha->8)-ent-epicatechin, epicatechin-(4beta->8)-epicatechin-3-O-gallate, neorhusflavanone, and cyanidin 3-(6''-caffeylsophoroside)-5-glucoside. An in vitro study must be conducted to explore the DNMT1 inhibitory potential of these five compounds.
